List of Excipients in Branded Drug CHILDRENS MOTRIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Kenvue Brands LLC	CHILDRENS MOTRIN	ibuprofen	50580-184	ACESULFAME POTASSIUM
Kenvue Brands LLC	CHILDRENS MOTRIN	ibuprofen	50580-184	ANHYDROUS CITRIC ACID
Kenvue Brands LLC	CHILDRENS MOTRIN	ibuprofen	50580-184	GLYCERIN

Generic Drugs Containing CHILDRENS MOTRIN

Company	Ingredient	NDC	Excipient
Kenvue Brands LLC	ibuprofen	50580-932	ACESULFAME POTASSIUM
Kenvue Brands LLC	ibuprofen	50580-932	AMMONIUM GLYCYRRHIZATE
Kenvue Brands LLC	ibuprofen	50580-932	ASPARTAME

What are the Most Frequently-Used Excipients in CHILDRENS MOTRIN?

# Of NDCs	Excipient
2	ACESULFAME POTASSIUM
2	AMMONIUM GLYCYRRHIZATE
2	ASPARTAME

Children's Motrin Excipient Strategy and Commercial Opportunities

Last updated: August 25, 2026

Children's Motrin is an ibuprofen-based over-the-counter oral suspension whose commercial value comes primarily from brand recognition, dosing convenience, flavor acceptance, and retail distribution rather than patent exclusivity. The standard product contains 100 mg of ibuprofen per 5 mL and relies on suspending agents, preservatives, sweeteners, flavor, and viscosity control to deliver a stable pediatric liquid dose.[1]

The strongest commercial opportunities are dye-free and sugar-reduced formulations, improved dose-measuring systems, differentiated flavor platforms, preservative reduction, and private-label products that compete on price while matching the branded product's usability.

What is Children's Motrin and how is it regulated?

Children's Motrin is an OTC pediatric ibuprofen suspension used for temporary reduction of fever and relief of minor aches and pains. In the United States, the principal marketed concentration is 100 mg per 5 mL.[1]

Product and regulatory profile

Attribute	Children's Motrin profile
Active ingredient	Ibuprofen
Common concentration	100 mg per 5 mL
Dosage form	Oral suspension
Therapeutic category	OTC analgesic and antipyretic
Primary users	Children and caregivers
U.S. regulatory pathway	OTC monograph framework
Common manufacturer or marketer	Kenvue-associated Motrin brand operations
Prescription status	Nonprescription
Orange Book status	Generally not an Orange Book-listed prescription product
Primary commercial risks	Generic and private-label substitution, price competition, retailer shelf allocation
Principal formulation assets	Suspension stability, taste masking, dose uniformity, packaging, and consumer usability

Ibuprofen products are regulated under the FDA's OTC internal analgesic, antipyretic, and antirheumatic framework, including 21 C.F.R. Part 343 and the applicable OTC monograph requirements.[2] A branded OTC product does not receive the same market protection as a new prescription drug approved through a full New Drug Application.

What excipients are used in Children's Motrin?

The Children's Motrin oral suspension label identifies excipients that support suspension stability, palatability, preservation, viscosity, and consumer acceptance.[1]

Core excipient functions

Excipient or excipient class	Likely formulation role	Commercial relevance
Microcrystalline cellulose and carboxymethylcellulose sodium	Suspending and rheology system	Keeps ibuprofen particles dispersed and supports dose uniformity
Xanthan gum	Viscosity modifier and suspension aid	Improves physical stability but can increase pour resistance
Glycerin	Humectant, solvent, and mouthfeel modifier	Supports sweetness and liquid texture
Sucrose	Sweetener and palatability enhancer	Improves acceptance but creates sugar-content and dental-health concerns
Polysorbate 80	Wetting and dispersion aid	Helps disperse hydrophobic ibuprofen
Sodium benzoate	Preservative	Controls microbial growth in an aqueous multidose product
Citric acid and sodium chloride	pH, taste, and formulation adjustment	Supports product stability and sensory profile
Flavor system	Taste masking	Directly affects repeat use and caregiver preference
FD&C Red No. 40 in applicable versions	Colorant	Product identification and visual differentiation
Purified water	Vehicle	Main liquid phase

The excipient system has to solve a difficult technical problem: ibuprofen is poorly water-soluble, while pediatric liquid products require accurate dosing from a heterogeneous suspension. The formulation must redisperse after storage, resist sediment compaction, remain microbiologically controlled, and provide acceptable taste at the labeled dose.

How strong is the Children's Motrin formulation strategy?

The formulation strategy is technically established but commercially vulnerable. Most listed excipients are standard pharmaceutical ingredients with broad supplier availability. They are unlikely to create a significant standalone barrier to generic or private-label entry.

Technical strengths

The standard suspension design has four important strengths:

1. It uses a recognized suspending-agent system for a poorly water-soluble active ingredient.
2. It combines sweetener, glycerin, and flavor to reduce ibuprofen's bitter taste.
3. It uses a multidose preservative system suitable for repeated household opening.
4. It supports a familiar 100 mg per 5 mL concentration across pediatric products.

The commercial weakness is that competitors can reproduce the same basic architecture. The strongest defensible value is likely in the integrated package of formulation, flavor profile, bottle design, dosing syringe or cup, brand equity, and distribution.

Critical quality attributes

A competing or improved product must control:

• Ibuprofen concentration per labeled volume
• Particle-size distribution
• Redispersibility after sedimentation
• Viscosity and pourability
• Microbial limits throughout in-use storage
• Preservative effectiveness
• pH and chemical stability
• Dose delivery from the supplied measuring device
• Flavor and aftertaste
• Container-closure compatibility

A formulation that is too viscous may improve suspension stability but make dosing difficult. A formulation that is too thin may pour easily but settle rapidly. This tradeoff creates a practical opportunity for formulation optimization even when the active ingredient is off-patent.

What patents protect Children's Motrin?

No material patent exclusivity is associated with ibuprofen itself. The active ingredient has been marketed for decades, and basic ibuprofen composition-of-matter protection is expired.

Orange Book and patent position

Children's Motrin is an OTC product rather than a conventional prescription NDA product. The FDA Orange Book primarily identifies approved prescription drug products, therapeutic equivalence evaluations, and patent or exclusivity information associated with listed applications.[3]

Protection category	Assessment
Ibuprofen composition patent	Expired
Basic oral ibuprofen suspension concept	Not a meaningful current barrier
OTC monograph protection	No brand-specific exclusivity
Orange Book patent listing	Generally not applicable to the marketed OTC product
Paragraph IV exposure	Not the normal competitive pathway for an OTC monograph product
Trademark protection	Motrin brand and related marks remain commercially important
Trade dress and packaging	Potentially relevant, subject to trademark and trade-dress law
Proprietary flavor or process know-how	Could exist, but is not equivalent to broad market exclusivity
Formulation patent opportunity	Possible for genuinely differentiated systems, but requires non-obvious technical performance

Are there formulation patents for Children's Motrin?

A formulation patent could protect a specific suspension system, taste-masking technology, preservative combination, container, or dosing device. Such protection would need to cover a defined technical combination and survive validity challenges. The presence of the same or similar excipients in a commercial label does not establish that the product is protected by a live patent.

For a competitor, the practical freedom-to-operate risk is more likely to arise from a specific later-filed formulation, packaging, or delivery patent than from ibuprofen itself. A generic manufacturer should search U.S. and foreign patent databases for claims directed to:

• Ibuprofen particle engineering
• Taste-masked ibuprofen suspensions
• Low-sugar or sugar-free oral liquids
• Preservative systems
• Child-resistant and senior-friendly closures
• Oral dosing syringes and flow restrictors
• Unit-dose sachets or stick packs
• Extended stability after opening
• Combination products containing ibuprofen and another active ingredient

When does Children's Motrin lose exclusivity?

Children's Motrin has no meaningful remaining patent exclusivity in the active ingredient. Its commercial exclusivity is brand-based and can be challenged by private-label products at any time, subject to FDA compliance and trademark restrictions.

Exclusivity timeline

Milestone	Commercial effect
Ibuprofen introduced as a prescription medicine	Established clinical and manufacturing precedent
OTC ibuprofen launch	Expanded consumer market
Expiration of foundational ibuprofen patents	Enabled broad generic and private-label competition
OTC monograph regulation	Reduced dependence on brand-specific approval exclusivity
Current market	Competition based on price, formulation, packaging, retail presence, and trust

There is no standard five-year new chemical entity exclusivity period attached to the current Children's Motrin product. There is also no pediatric exclusivity period that creates a current barrier around the established OTC suspension.

What formulation patents could create commercial opportunity?

The most attractive patent opportunities are narrow, performance-based improvements rather than basic ibuprofen suspensions.

High-value formulation concepts

Dye-free suspension

A dye-free product addresses consumer concerns about colorants and may expand use among children whose caregivers avoid artificial dyes. The technical challenge is preserving visual product identity without color. A strong patent position would require more than simply removing FD&C Red No. 40. It could involve a defined stabilizer, flavor, and viscosity system that maintains dose uniformity and shelf life.

Sugar-free or reduced-sugar formulation

Replacing sucrose can support dental-health positioning and appeal to caregivers seeking lower sugar content. Candidate systems include sorbitol, sucralose, acesulfame potassium, steviol glycosides, maltitol, or combinations of sweeteners and polyols.

The main development issues are:

• Bitter aftertaste from ibuprofen
• Cooling or laxative effects from polyols
• Higher preservative burden
• Changes in viscosity
• Flavor instability
• Consumer acceptance across different pediatric age groups

Preservative-reduced formulation

A preservative-free or preservative-reduced multidose suspension would have strong differentiation potential, but it requires a credible microbiological-control strategy. Possible approaches include unit-dose packaging, single-use sachets, antimicrobial container systems, aseptic manufacturing, or a validated low-water-activity formulation.

Improved dosing system

Dose accuracy is a direct commercial opportunity. A bottle with an integrated oral syringe, flow restrictor, anti-drip neck, or calibrated dosing adapter could reduce household measurement errors. Packaging claims must be supported by human-factors and dose-delivery testing.

Faster redispersion

A suspension that redisperses with fewer shakes would improve caregiver usability. Patentable value could arise from controlled particle size, structured vehicles, polymer combinations, or flocculation technology. The product would need measurable superiority in sedimentation, redispersion time, and delivered-dose uniformity.

What commercial opportunities exist for Children's Motrin competitors?

The market is mature, but product differentiation remains available.

Opportunity ranking

Opportunity	Consumer value	Technical difficulty	Patent potential	Commercial outlook
Dye-free suspension	High	Low to moderate	Low to moderate	Strong
Sugar-free suspension	High	Moderate	Moderate	Strong
Premium flavor system	High	Moderate	Low	Strong if supported by testing
Integrated oral syringe	High	Moderate	Moderate	Strong
Unit-dose preservative-free product	Moderate to high	High	Moderate to high	Attractive but capital-intensive
Faster-redispersing suspension	Moderate	Moderate	Moderate	Selective
Pediatric combination product	High	High	High	Regulatory and safety complexity
Low-cost private-label suspension	Moderate	Low	Low	High-volume, low-margin
Travel-size or stick-pack format	Moderate	Moderate	Moderate	Niche growth
Organic or "natural" positioning	Variable	Moderate	Low	Marketing-led rather than patent-led

Private-label retailers can compete effectively with a compliant 100 mg per 5 mL ibuprofen suspension because the active ingredient and basic excipient technology are widely available. Their principal advantages are lower price and retailer control. The branded product retains advantages in recognition, perceived reliability, distribution, and caregiver familiarity.

Which companies are challenging Children's Motrin?

Competition comes from several groups:

• Retail private-label ibuprofen products
• National pediatric analgesic brands
• Adult ibuprofen brands offering pediatric or family-use products
• Generic manufacturers supplying store brands
• Pediatric combination-product manufacturers
• E-commerce and direct-to-consumer brands

The principal competitive comparison is not usually between patented molecules. It is between branded and private-label versions of the same active ingredient and concentration.

Brand-versus-private-label comparison

Factor	Children's Motrin	Private-label ibuprofen
Active ingredient	Ibuprofen	Ibuprofen
Standard concentration	Commonly 100 mg per 5 mL	Commonly 100 mg per 5 mL
Brand recognition	High	Low to moderate
Price	Usually premium	Usually lower
Formulation similarity	Often close	Often close
Flavor differentiation	Brand-dependent	Retailer-dependent
Patent barrier	Limited	Limited
Shelf placement	Strong where brand-supported	Strong in value-focused channels
Main purchase driver	Trust and familiarity	Price and availability

What is the FDA status of Children's Motrin?

Children's Motrin is an OTC ibuprofen product marketed under the FDA framework for internal analgesic and antipyretic products. The product label includes age-specific directions, warnings concerning allergic reactions and stomach bleeding, and instructions to seek professional advice for children below the labeled age threshold.[1][2]

FDA compliance priorities for a new competitor include:

• Use of a permitted active ingredient and dosage
• Compliance with the OTC monograph
• Drug Facts labeling
• Appropriate pediatric directions
• Stability data
• Microbial quality
• Preservative effectiveness
• Child-resistant packaging where required
• Accurate dosing device labeling
• Advertising substantiation
• Compliance with current manufacturing requirements

An OTC monograph-compliant product generally does not require a Paragraph IV certification. Paragraph IV litigation is associated primarily with ANDA applicants challenging patents listed for prescription drug products in the Orange Book.[3]

What litigation and settlement risks affect Children's Motrin?

The main legal risks are commercial rather than patent-settlement driven.

Relevant risk categories

Risk	Relevance
Paragraph IV litigation	Limited for an OTC monograph product
Composition-of-matter patent litigation	No current practical risk for ibuprofen
Formulation patent litigation	Possible if a later patent covers a specific suspension or packaging system
Trademark infringement	Material for use of Motrin branding or confusingly similar marks
Trade-dress disputes	Possible where packaging imitates branded presentation
False advertising	Possible for claims about superior taste, faster action, safety, or dosing accuracy
Product liability	Material because the product is used in children
Labeling enforcement	Material if age, dose, warning, or ingredient information is inaccurate
Recall exposure	Possible for contamination, potency variation, or dosing-device errors

No standard generic-entry settlement structure is expected to govern competition against the OTC product. Market entry generally depends on formulation development, manufacturing readiness, FDA compliance, and retailer acceptance.

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers are moderate, not high. Ibuprofen is widely available, and the core excipients are commodity or widely used pharmaceutical ingredients. The harder requirements are process control and product consistency.

Manufacturing requirements

A commercial manufacturer must manage:

• Uniform dispersion of ibuprofen
• Controlled addition of polymers and surfactants
• Avoidance of agglomeration
• Consistent viscosity across batches
• Robust filling into bottles
• Accurate bottle and dosing-device fit
• Preservative distribution
• Long-term and in-use stability
• Packaging compatibility
• Flavor consistency

The strongest manufacturing moat is process know-how. A company may achieve a stable suspension in development but fail during scale-up because mixing energy, order of addition, shear, temperature, or hold time changes the suspension structure.

Geographic coverage is also commercially relevant. U.S. OTC monograph compliance does not automatically establish approval in Canada, the European Union, the United Kingdom, Japan, or other markets. Each jurisdiction applies its own rules for ibuprofen dosage, pediatric labeling, excipients, colorants, preservatives, and packaging.

What revenue exposure does Children's Motrin create?

Public brand-level revenue for Children's Motrin is generally not separately disclosed. The commercial exposure is concentrated in the pediatric analgesic and fever-reducer segment, where demand is seasonal and highly sensitive to respiratory illness trends, retailer inventory, product recalls, and consumer switching.

Revenue drivers include:

• Winter respiratory-virus seasons
• Pediatric fever incidence
• Retailer promotion
• Brand and private-label price gaps
• Product availability
• Flavor and dosage-device preferences
• Caregiver trust
• Pediatric product safety concerns
• E-commerce fulfillment and search placement

A manufacturer evaluating entry should model volume by channel rather than assume brand-level market share translates directly into prescription-style exclusivity. Grocery, mass retail, pharmacy, club, and online channels have different margins and promotional economics.

Key Takeaways

• Children's Motrin is primarily a branded OTC ibuprofen suspension, not a patent-protected prescription product.
• The common formulation contains 100 mg of ibuprofen per 5 mL and uses suspending agents, sweeteners, glycerin, flavor, preservative, and viscosity modifiers.
• Ibuprofen composition-of-matter exclusivity has expired.
• The FDA Orange Book and Paragraph IV framework have limited relevance to the current OTC monograph product.
• The main defensible assets are brand equity, flavor acceptance, packaging, dosing convenience, manufacturing know-how, and retailer distribution.
• Dye-free, sugar-free, preservative-reduced, unit-dose, and improved-dose-delivery products offer the clearest commercial opportunities.
• A new formulation patent would need to claim a specific technical combination with measurable performance, not merely a conventional ibuprofen suspension.
• Generic and private-label entry risk is high because the active ingredient and core excipient technology are widely available.
• The principal legal risks involve formulation patents, trademarks, trade dress, labeling, advertising, and product liability.
• Revenue exposure is driven by pediatric seasonal demand, retail distribution, price competition, and product availability rather than patent expiration.

FAQs About Children's Motrin Excipient Strategy

Is Children's Motrin sugar-free?

The standard Children's Motrin oral suspension label identifies sucrose as an inactive ingredient.[1] Sugar-free versions require a separate formulation and labeling assessment because sweetener replacement can affect taste, viscosity, preservative performance, and stability.

Does Children's Motrin contain artificial dye?

Applicable Children's Motrin suspension labels identify FD&C Red No. 40 as an inactive ingredient.[1] Dye-free alternatives can compete through a distinct excipient and packaging strategy.

Can a company make a generic version of Children's Motrin?

Yes. A company can market an OTC ibuprofen suspension that complies with the FDA monograph and applicable labeling, manufacturing, stability, packaging, and quality requirements. It cannot use Motrin trademarks or confusingly similar trade dress.

What is the most attractive patent opportunity in pediatric ibuprofen liquids?

The strongest opportunities are likely to involve a defined sugar-free or dye-free suspension system, improved taste masking, enhanced redispersion, preservative reduction, or an integrated dosing package with demonstrated performance benefits.

Does Children's Motrin have biosimilar risk?

No. Ibuprofen is a chemically synthesized small molecule, not a biologic. The relevant competitive risks are generic, private-label, branded OTC, and combination-product competition rather than biosimilar substitution.

References

1. Kenvue Brands LLC. (n.d.). Children's Motrin oral suspension, 100 mg/5 mL: Drug facts label. DailyMed.
2. U.S. Food and Drug Administration. (2024). 21 C.F.R. Part 343: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use. Electronic Code of Federal Regulations.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.